other material
confidence high
sentiment positive
materiality 0.85
Summit reports ivonescimab beats Keytruda in Phase 3 NSCLC trial; PFS HR=0.51 p<0.0001
Summit Therapeutics Inc.
- Ivonescimab vs pembrolizumab in 1L PD-L1+ advanced NSCLC: mPFS 11.14 vs 5.82 months (HR 0.51, p<0.0001).
- ORR 50.0% vs 38.5%, DCR 89.9% vs 70.5%. OS not yet mature; safety manageable.
- Subgroup benefit consistent: PD-L1 TPS≥50% HR 0.46; squamous HR 0.48; non-squamous HR 0.54.
- Phase II perioperative AK112-205 in resectable NSCLC: MPR 71.8% (cohort 2), pCR 43.6% with ivonescimab+chemo.
- Additional Phase II data in breast, colorectal, head & neck cancers released at ESMO; conference call Sep 9.